Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,561 to 4,580 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Prolonged RBC Storage vs Short RBC Storage: Effect of RBC Age on Occurrence of Pulmonary Events. | 113 of 686 106 of 701 | 1.4 points -2.5 to 5.2 | 1,387 | NCT00458783 Red Cell Storage Duration and Outcomes in Cardiac Surgery |
| Prolonged RBC Storage vs Short RBC Storage: deaths from any cause | 23 of 686 15 of 701 | 1.2 points -0.5 to 3.0 | 1,387 | NCT00458783 Red Cell Storage Duration and Outcomes in Cardiac Surgery |
| Prolonged RBC Storage vs Short RBC Storage: serious adverse events | 360 of 686 362 of 701 | 0.8 points -4.4 to 6.1 | 1,387 | NCT00458783 Red Cell Storage Duration and Outcomes in Cardiac Surgery |
| Arm A: EC-T vs Arm B: ET-X: Number of Participants With Disease-free Survival (DFS) Event | 127 of 669 170 of 715 | -4.8 points -9.1 to -0.5 | 1,384 | NCT00129935 EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer |
| Arm A: EC-T vs Arm B: ET-X: deaths from any cause | 70 of 669 83 of 715 | -1.1 points -4.5 to 2.2 | 1,384 | NCT00129935 EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer |
| Arm A: EC-T vs Arm B: ET-X: Number of Participants With Overall Survival (OS) Event | 70 of 669 83 of 715 | -1.1 points -4.5 to 2.2 | 1,384 | NCT00129935 EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer |
| Arm A: EC-T vs Arm B: ET-X: serious adverse events | 111 of 669 138 of 715 | -2.7 points -6.7 to 1.4 | 1,384 | NCT00129935 EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer |
| Nitric Oxide Releasing Solution vs Placebo: Number of Participants Reporting Safety Concerns. | 129 of 690 130 of 694 | -0.0 points -4.1 to 4.1 | 1,384 | NCT05109611 Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection |
| Nitric Oxide Releasing Solution vs Placebo: Number of Participants Requiring Medical Services. | 1 of 690 0 of 694 | 0.1 points -0.4 to 0.8 | 1,384 | NCT05109611 Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection |
| Nitric Oxide Releasing Solution vs Placebo: Number of Participants With a COVID-19 Infection. | 2 of 690 2 of 694 | 0.0 points -0.8 to 0.8 | 1,384 | NCT05109611 Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection |
| Nitric Oxide Releasing Solution vs Placebo: serious adverse events | 1 of 690 0 of 694 | 0.1 points -0.4 to 0.8 | 1,384 | NCT05109611 Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection |
| Boostrix Group vs Adacel Group: Number of Subjects With Anti-D Antibody Concentrations ≥ Protocol Specified Cut-off | 857 of 934 425 of 449 | -2.9 points -5.5 to 0.1 | 1,383 | NCT00489970 Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 |
| Restrictive vs Liberal: A Composite Endpoint of All-cause Mortality, MI, Coronary Revascularization, Acute Renal Failure, or Postoperative Ischemic Stroke | 45 of 703 33 of 680 | 1.5 points -0.9 to 4.0 | 1,383 | NCT03229941 Transfusion Trigger After Operations in High Cardiac Risk Patients |
| DDLPS Patients With 1L Treatment at Index Date (Cohort 1) vs DDLPS Patients Without 1L Treatment at Index Date (Cohort 2): deaths from any cause | 175 of 275 423 of 1,106 | 25.4 points 18.9 to 31.5 | 1,381 | NCT06115681 Real-world Study of Dedifferentiated Liposarcoma Patients in China |
| Reimbursement for Smoking Cessation Therapy (SCT) vs No Reimbursement for SCT: serious adverse events | 35 of 696 25 of 684 | 1.4 points -0.8 to 3.6 | 1,380 | NCT00818207 Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit |
| Boostrix Group vs Adacel Group: Number of Subjects With Anti-T Antibody Concentrations ≥ Protocol Specified Cut-off | 899 of 937 440 of 442 | -3.6 points -5.1 to -2.0 | 1,379 | NCT00489970 Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 |
| Arm A: EC-T vs Arm B: ET-X: The Number of Participants Who Experienced Adverse Events (AE) | 665 of 667 699 of 711 | 1.4 points 0.3 to 2.6 | 1,378 | NCT00129935 EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer |
| CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: Number of Patients With Optimal Glucose Control | 141 of 659 159 of 719 | -0.7 points -5.1 to 3.7 | 1,378 | NCT03890588 Chronic Kidney Disease Clinical Decision Support |
| Edoxaban vs Vitamin K Antagonist (VKA): deaths from any cause | 83 of 693 78 of 684 | 0.6 points -2.8 to 4.0 | 1,377 | NCT02943785 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) |
| Edoxaban vs Vitamin K Antagonist (VKA): serious adverse events | 388 of 693 372 of 684 | 1.6 points -3.6 to 6.8 | 1,377 | NCT02943785 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=229"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=229
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00458783-d27ffc31",
"title": "Prolonged RBC Storage vs Short RBC Storage: Effect of RBC Age on Occurrence of Pulmonary Events.",
"summary": "113 of 686 against 106 of 701; risk difference 1.4 points, 95% interval -2.5 to 5.2; NCT00458783, Red Cell Storage Duration and Outcomes in Cardiac Surgery",
"record": "/library/comparisons/NCT00458783-d27ffc31",
"nct_id": "NCT00458783",
"kind": "outcome",
"participants": 1387,
"risk_difference": {
"value": 0.013510478574963708,
"lower": -0.02492263872583205,
"upper": 0.0520159103541047
},
"group_1": "113 of 686",
"group_2": "106 of 701",
"difference": "1.4 points",
"interval": "-2.5 to 5.2",
"trial_title": "Red Cell Storage Duration and Outcomes in Cardiac Surgery"
},
{
"id": "NCT00458783-deaths",
"title": "Prolonged RBC Storage vs Short RBC Storage: deaths from any cause",
"summary": "23 of 686 against 15 of 701; risk difference 1.2 points, 95% interval -0.5 to 3.0; NCT00458783, Red Cell Storage Duration and Outcomes in Cardiac Surgery",
"record": "/library/comparisons/NCT00458783-deaths",
"nct_id": "NCT00458783",
"kind": "deaths",
"participants": 1387,
"risk_difference": {
"value": 0.01212969393993587,
"lower": -0.005419124148746301,
"upper": 0.030443145217861532
},
"group_1": "23 of 686",
"group_2": "15 of 701",
"difference": "1.2 points",
"interval": "-0.5 to 3.0",
"trial_title": "Red Cell Storage Duration and Outcomes in Cardiac Surgery"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=230",
"request_id": "9_o_WFX3c8XR_imk"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant